Do you want to read an article? Please log in or register.
Effectiveness of NELSON versus PLCOm2012 lung cancer screening eligibility criteria in Germany (HANSE): a prospective cohort study
Lung Cancer
COMMENTED
Related content
Lung Cancer
Lung Cancer Screening Adherence in Centralized versus Decentralized Screening Programs A Meta-Analysis of U.S. Cohort Studies Among Individuals with Negative Baseline Results
Chest
Ezenwankwo E, Jones C, Nguyen DT, Eberth JM
doi: 10.1016/j.chest.2025.04.033
Interstitial Lung Disease
Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multi-centre cohort study
Eur Respir J
Wu W, Guo B, Sun W, Chen D, Xu W, Chen Z, Fu Y, Ye Y, Lyu X, Xue Z, Wang K, Zhao J, Xie C, Chen Y, Ye C, Dai M, Fan W, Li J, Wang X, Xue Y, Wan W, Sun L, Wu H, Luo Q, Han Q, Fu Q, Ye S
doi: 10.1183/13993003.01488-2024
RECOMMENDED
Lung CancerFurther Publications
Physical activity and lung cancer screening (PALS): feasibility randomised controlled trial of exercise and physical activity in lung cancer screening
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Res
Bonney A, Granger CL, Steinfort D, Patrick C, Marshall HM, Fong KM, Manser R
doi: 10.1186/s12931-025-03158-0
Lung Cancer
A comparative analysis of heterogeneity in lung cancer screening effectiveness in two randomised controlled trials
Nat Commun
Welz M, van der Aalst CM, Alfons A, Naghi AA, Heuvelmans MA, Groen HJM, de Jong PA, Aerts J, Oudkerk M, de Koning HJ, Ten Haaf K, NELSON trial consortium
doi: 10.1038/s41467-025-63471-6
RECOMMENDED
Lung Cancer
Completion Rates for Patients Undergoing Concurrent Chemoradiotherapy for Stage III Nonsmall Cell Lung Cancer and its Importance in the Era of Consolidation Immunotherapy: A Cohort Study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Wallace ND, Xie J, Alexander M, Ball D, Hegi-Johnson F, Plumridge N, Siva S, Shaw M, Harden S, John T, Solomon B, Irving L, Duffy M, Officer A, MacManus M
doi: 10.1016/j.cllc.2025.02.010
Lung Cancer
Comparative Effectiveness of Nivolumab and Ipilimumab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in PD-L1 Negative Metastatic Non-Small Cell Lung Cancer Patients
Clin Lung Cancer
Verschueren MV, Hiensch DTA, Plomp PMJ, Kastelijn LA, van de Garde EMW, Peters BJM
doi: 10.1016/j.cllc.2025.01.009
RECOMMENDED
Lung Cancer
The PESGA Trial: A Prospective, Open-Label, Single-Arm, Phase II Study to Evaluate First Line Therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients, Treated by Induction Carboplatin/Etoposide/Pembrolizumab Followed by Maintenance of Pembrolizumab/ Sacituzumab Govitecan
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Clin Lung Cancer
Roisman LC, Mann S, Basel A, Marei R, Krayim B, Kornev G, Asna N, Peled N
doi: 10.1016/j.cllc.2025.02.002
RECOMMENDED
Lung Cancer
Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Chouaid C, Bosquet L, Knott C, Li Z, Schaeffer M, Lin X, Schioppa CA, Perualila NJ, Diels J, Caparros EQ, Galea F, Hultén A, Greystoke A
doi: 10.1016/j.lungcan.2025.108548
RECOMMENDED
Lung Cancer
Regimen Selection for Chemoimmunotherapy in Nonsquamous Non-Small Cell Lung Cancer with Low PD-L1 Expression: A Multicenter Retrospective Cohort Study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Clin Lung Cancer
Hata T, Yamada T, Goto Y, Amano A, Negi Y, Watanabe S, Furuya N, Oba T, Ikoma T, Nakao A, Tanimura K, Taniguchi H, Yoshimura A, Fukui T, Murata D, Kaira K, Shiotsu S, Hibino M, Okada A, Chihara Y, Kawachi H, Kijima T, Takayama K
doi: 10.1016/j.cllc.2025.01.002